|Day Low/High||81.43 / 81.48|
|52 Wk Low/High||26.41 / 63.34|
These favorite names in the volatile sector offer the potential for high rewards.
OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.
David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.
AstraZeneca shares, meanwhile, were less-than-moved by the news.
The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
The thwarted Medivation bidder lifts its full-year earnings estimates and announces a share buyback program.
A day after winning approval for a cancer drug, Merck posts earnings and sales that beat consensus estimates.
Slower declines in diabetes drug sales and an acceleration in new oncology treatment Praluent are key to a good quarter for the French drugs maker.
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.
Despite markets at record highs, companies are satisfying their appetites to grow and find value by buying others.
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Medivation, Inc.
The company has spent $600 million weighing a potential breakup.
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer's pending acquisition of Medivation, Inc.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medivation, Inc.
So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.
There are too many companies in just about every sector of this market, Cramer says.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Medivation, Inc.
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
Pfizer is making another acquisition.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.